Optimizing Care for Older Adults through Thyroid Hormone Deprescribing

通过减少甲状腺激素处方来优化老年人的护理

基本信息

  • 批准号:
    10733478
  • 负责人:
  • 金额:
    $ 79.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2028-08-31
  • 项目状态:
    未结题

项目摘要

Abstract/Project Summary Older adults have a disproportionately higher prevalence of hypothyroidism compared to their younger counterparts, with levothyroxine (the most widely used synthetic thyroid hormone) consistently one of the top most frequently prescribed medications in the United States. Alarmingly, up to 48% of older adults aged 65 years receive a thyroid hormone dose that is too high, resulting in overtreatment. In addition, thyroid hormone therapy is often initiated for inappropriate indications (misuse) which can also lead to overtreatment. This is especially concerning for older adults, who comprise the fastest growing demographic group and the most vulnerable to polypharmacy. Studies conducted by our team and others have demonstrated that thyroid hormone overtreatment can lead to significant cardiovascular and skeletal risks, and increased mortality. Despite potential patient harm, ~90% of patients continue lifelong thyroid hormone treatment. Thus, in the context of thyroid hormone overtreatment, there is a critical need to deprescribe, which can be achieved either via thyroid hormone dose de-escalation (in patients overtreated) or thyroid hormone discontinuation (in patients without an appropriate indication). The proposed study is the first multi-site trial to evaluate a novel evidence-based adapted multilevel intervention, D-THIO (Deprescribing Thyroid Hormone In Older Adults), consisting of evidence-based pharmaceutical opinion letters to providers, education brochures to patients and facilitated by clinical champions, to support thyroid hormone deprescribing in older adults. We will conduct a type 1 hybrid effectiveness- implementation trial of D-THIO vs. enhanced usual care (American Thyroid Association [ATA] provider abbreviated guidelines, ATA patient brochure) at 3 sites (University of Michigan, Henry Ford, University of California San Francisco) in 150 providers (primary care, endocrinologists, geriatricians, advance practice providers) and 750 of their patients 65 years overtreated with thyroid hormone. We will randomize 1:1 at the provider level within each site. We propose three specific aims: 1) to assess the effectiveness of D-THIO on thyroid hormone deprescribing by providers and on reducing overtreatment and misuse with thyroid hormone via EMR, 2) to assess the effectiveness of D-THIO on provider and patient knowledge and attitudes regarding thyroid hormone deprescribing via surveys, and 3) to identify factors related to the implementation of D-THIO across diverse general care settings via post-trial interviews with key stakeholders. Ultimately, our findings will serve as a model for deprescribing inappropriate medications for other endocrine conditions and conditions with biochemical monitoring, and advance our understanding of de-implementation of low-value care in older adults across the nation.
摘要/项目摘要 与年轻人相比,老年人甲状腺功能减退症的患病率高得不成比例。 与左旋甲状腺素(最广泛使用的合成甲状腺激素)一直是最重要的 在美国最常见的处方药。令人担忧的是,高达48%的65岁以上的老年人 10岁以上的人接受的甲状腺激素剂量过高,导致过度治疗。此外,甲状腺激素 治疗通常是针对不适当的适应症(误用)开始的,这也可能导致过度治疗。这是 特别是老年人,他们是人口增长最快的群体, 易受多种药物治疗的影响我们的团队和其他人进行的研究表明,甲状腺激素 过度治疗可导致严重的心血管和骨骼风险,并增加死亡率。尽管有潜力 患者伤害,~90%的患者继续终身甲状腺激素治疗。因此,在甲状腺的背景下, 激素过度治疗,有一个关键需要取消,这可以通过甲状腺激素, 剂量递减(在过度治疗的患者中)或甲状腺激素停药(在没有 适当的指示)。这项拟议的研究是第一个多中心试验,以评估一种新的循证适应 多层次干预,D-THIO(老年人甲状腺激素处方),包括基于证据的 给提供者的药物意见书,给患者的教育手册,并由临床冠军提供便利, 来支持老年人减少甲状腺激素的使用。我们将进行第一种混合效率- D-THIO与加强常规护理实施试验(美国甲状腺协会[ATA]提供者 简要指南,ATA患者手册)在3个研究中心(密歇根大学,亨利福特, 加州旧金山弗朗西斯科)的150名提供者(初级保健、内分泌学家、老年病学家、高级实践 提供者)和750名65岁以上的患者过度使用甲状腺激素。我们将随机1:1在 每个站点内的供应商级别。我们提出了三个具体目标:1)评估D-THIO对 提供者取消甲状腺激素处方,减少过度治疗和滥用甲状腺激素 通过EMR,2)评估D-THIO对提供者和患者知识和态度的有效性, 通过调查确定甲状腺激素处方,以及3)确定与D-THIO实施相关的因素 通过与关键利益相关者的试验后访谈,在不同的一般护理环境中进行。最终,我们的发现将 作为一个模式,取消不适当的药物治疗其他内分泌疾病和条件, 生化监测,并推进我们对老年人低价值护理的理解 在全国范围内。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria Papaleontiou其他文献

Maria Papaleontiou的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria Papaleontiou', 18)}}的其他基金

The Effect of Inappropriate Use of Thyroid Hormone Replacement in Older Men
不适当使用甲状腺激素替代品对老年男性的影响
  • 批准号:
    9352724
  • 财政年份:
    2016
  • 资助金额:
    $ 79.57万
  • 项目类别:
The Effect of Inappropriate Use of Thyroid Hormone Replacement in Older Men
不适当使用甲状腺激素替代品对老年男性的影响
  • 批准号:
    10591891
  • 财政年份:
    2016
  • 资助金额:
    $ 79.57万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 79.57万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 79.57万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 79.57万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了